We present the case of a 52-year-old woman with recurrent disseminated coccidioidomycosis involving the larynx that was associated with vocal fold paralysis. Th e diagnosis was confi rmed by histologic biopsy, and the patient had an excellent response to systemic antifungal treatment. However, her vocal fold motion did not return. We also review the current world literature.
Introduction
Coccidioidomycosis is an uncommon fungal infection seen primarily in areas of California, Arizona, and northern Mexico where the Coccidioides immitis fungus is ubiquitous in soil and dust. As many as 20% of cases may be identifi ed in nonendemic areas, especially in patients who have traveled through regions known to be the habitat of C immitis. 1 Inhalation is the primary method of inoculation. Patients with the infection are frequently asymptomatic, 1 but disseminated infection has occurred in a small number of cases [2] [3] [4] [5] [6] [7] [8] [9] [10] and has caused symptoms in multiple sites, including the larynx and tracheobronchial tree.
Treatment of coccidioidomycosis with systemic antifungal medication such as fl uconazole is usually successful; surgery is required for airway stabilization and occasionally for debridement. 5, 11 Reactivation, particularly in immunocompromised patients, can occur many years later. 3, 5 Until now, no case of laryngeal C immitis infection has been described in association with vocal fold motion abnormalities. We report such a case.
Case report
Our patient was a 52-year-old woman with a history of pulmonary coccidioidomycosis that was diagnosed in 1984 and treated with antifungals until 1998; treatment was stopped when she went into remission. In December 2007, she presented to the Center for Voice and Swallowing at the University of California (UC) Davis Medical Center in Sacramento for evaluation of a 1-year history of nonprogressive dysphonia and cough. Her Voice Handicap Index was 34. Her regular medication regimen included daily prednisone therapy. She was known to have chronic bronchiectatic pulmonary changes consistent with prolonged C immitis infection.
Examination revealed that the patient's left vocal fold was immobile in the paramedian position. No mucosal abnormalities were noted, and the patient did not undergo imaging of the recurrent laryngeal nerve at this time. She was employed as a schoolteacher and therefore had excessive demands placed on her voice, but she lived some distance from the UC Davis Medical Center, and a regular voice therapy program was not convenient. Instead, she opted to undergo medialization. One month aft er presentation, the patient underwent an in-offi ce left vocal fold medialization via a thyrohyoid approach with calcium hydroxyapatite injection. 12 She experienced immediate vocal improvement.
Th ree weeks aft er the injection, however, the patient returned to our center complaining of weight loss, odynophagia, and dysphagia. Videolaryngoscopy demonstrated severe erythema, edema, and a pseudomembranous exudate involving the epiglottis, aryepiglottic folds, and piriform fossa (fi gure 1). Th e left vocal fold was again immobile as it had been previously, but it was well medialized. No lymphadenopathy was found, and the results of a cutaneous examination were normal. Assessment of the esophagus via transnasal esophagoscopy did not detect any involvement. Chest examination revealed upper-lobe expiratory wheezing. Computed tomography (CT) of the chest demonstrated large pneumoceles and lung foreign-body giant cells form granulomata. 1, 3, 5, 8, 10, 16, 17 When dissemination occurs, the fungus can aff ect any organ system. 5, 18 Approximately 7% of cases have involved the head and neck, with the larynx being a well-documented site. 2, 3, 5, [8] [9] [10] [18] [19] [20] [21] Other common sites of involvement include the skin, lymph nodes, meninges, and bone. 1, 11, 15, 19, 20, 22 Henley-Cohn et al documented a series of 4 cases treated at UC San Francisco; all 4 patients presented with airway distress, and all 4 cases damage bilaterally (fi gure 2). Th e coccidioidomycosis complement-fi xation titer (IgG) from blood was 1:32. Findings on cerebrospinal fl uid examination, human immunodefi ciency virus testing, urine culture, and magnetic resonance imaging (MRI) of the brain were within normal limits. Th e MRI did not demonstrate any skull base or intracranial involvement of C immitis. However, biopsies of the left vocal fold and the right arytenoid area did grow C immitis. Sputum cultures were also positive for the fungus.
Antifungal therapy was instituted with oral fl uconazole at 400 mg twice daily. A good response was seen with resolution of the laryngeal edema and exudate. Th e patient's odynophagia resolved, and she regained her lost weight. However, no change in the left vocal fold immobility was seen.
Aft er 6 weeks of antifungal therapy, follow-up laryngoscopy revealed a complete resolution of the erythema, edema, and exudate (fi gure 3), and the patient had no complaints of residual symptoms. However, the left vocal fold remained immobile and slightly undercorrected. She remained on extended fl uconazole antifungal treatment.
Discussion
Coccidioidomycosis was fi rst described in 1892 by Wernicke. 13 It was not until 1937 that C immitis was identifi ed as the source of the disease. 14 Th e fungal agent lives in the soil of the area to which it is endemic, and its arthroconidial (infectious) form is carried in dust, which is inhaled and deposited in the lower respiratory tract. 1, [3] [4] [5] [6] In most cases (60%) of coccidioidomycosis, asymptomatic or mild pulmonary infection occurs aft er an 8-to 30-day incubation period. 3, 7 Within the lung parenchyma, the conidia take the shape of spherules that contain endospores. Th e spherules trigger an immune response that is self-limiting in most immunocompetent people. 5 However, when the endospores they contain are released, dissemination of disease results. Approximately 40% of patients experience a reaction that is strong enough to cause moderate to severe pulmonary symptoms; these lung symptoms are oft en associated with fever, malaise, arthralgias, and night sweats, and occasionally with cutaneous signs such as erythema nodosum. [3] [4] [5] 8, 9 In fewer than 2% of cases, disease becomes disseminated, aggressive, or fulminant. 3, 5, 10, 15 Histologically, a mixed granulomatous and suppurative process occurs. Mononuclear infi ltrate is seen as macrophages phagocytose the spherules and involved deep neck space abscesses and adjacent cervical vertebral body infective changes. 16 Th e granulomatous nature of tissue infected by Coccidioides can be mistaken for fl orid carcinoma of the larynx, as has been described in other fungal diseases such as paracoccidioidomycosis and histoplasmosis. 3, 17, [22] [23] [24] Th ere may be erosion and ulceration, and submucosal masses have been described. 3, 20 In our patient, diff use edema and mucosal changes similar to a pseudomembrane were seen when she returned aft er augmentation with the vocal fold injection. Nodal disease in the neck may also present similarly to squamous cell carcinoma, as described by Newland and Komisar. 22 Th ere is debate over whether laryngeal infection represents a primary infection or the result of a direct inoculation from pulmonary secretions that carry the organism. 5, 9, 10, 16, 18 External compression and invasion of the trachea by infected paratracheal nodes have been described by Moskowitz et al 7 and Winter et al 25 in separate patients, and Beller et al 6 reported an obstructing endobronchial coccidioidal granuloma. In the past 50 years, fewer than a score of cases involving the larynx or tracheobronchial tree have been documented. 3, [5] [6] [7] 10, [18] [19] [20] [21] Both adults and children have been aff ected, and it seems that there is a male preponderance. 3, 8, 9, 18 Risk factors appear to be pregnancy and race; an increased prevalence has been reported in Mexican, Filipino, and black subgroups. 3, 4, 6, 7, 15, 17, 19 Immunocompromise has been noted as a risk factor for disseminated disease. 3, 4, 6, 15 Our patient had been on prolonged oral steroid treatment for pulmonary symptoms, and this might have contributed to the reactivation and spread of her disease. Also, injection of the vocal fold with calcium hydroxyapatite might have incited an infl ammatory response. It might be suggested that a foreign-body reaction could have stimulated a recrudescence of coccidioidal disease in our patient, but we believe that this was unlikely given that she had not previously exhibited any laryngeal symptoms other than vocal fold immobility and because calcium hydroxyapatite is generally well tolerated as an implant. Furthermore, the fi rst symptom that she had been aware of was cough, which suggests pulmonary disease that might have spread secondarily to the larynx. Imaging undertaken at the time of presentation did not detect any paralaryngeal nodal disease or cartilage involvement. We do realize, however, that it is not possible to be defi nitive about the source of the laryngeal coccidioidal spread.
Reactivation of coccidioidomycosis may occur months to years aft er the initial onset. 3, 5, 19 Hajare et al reported the case of a 31-month-old boy with laryngeal infection who had been immunosuppressed as a consequence of taking prednisone and cyclophosphamide for chronic glomerular sclerosis. 21 Twelve years later, Rosen et al described reactivation of the disease in the same patient, who was then 14 years old and who was still immunosuppressed aft er having received a live-donor kidney transplant. 5 Th e reactivation had occurred in the larynx, and it was proven by biopsy. For a second time, the patient responded to systemic antifungal treatment. Our patient had initially been treated with long-term antifungal therapy, but she still experienced a reactivation and dissemination of disease 10 years aft er discontinuation of treatment.
To the best of our knowledge, no report of vocal fold immobility in association with laryngeal coccidioidomycosis has been previously reported in the literature. Although symptoms of vocal palsy predated our patient's acute presentation, it is noted that she had had recurring pulmonary symptoms for many months prior to this. It is possible that the coccidioidal infection caused either local neural compromise or infl ammation and fi brosis such that vocal fold motion was inhibited. Th e failure of the vocal folds to regain full function following treatment, despite the excellent recovery of the appearance of the laryngeal mucosa, suggests that a neural cause is most likely.
Patients with a Coccidioides infection of the larynx oft en present with a threatened airway; approximately 50% of them need immediate airway intervention, either tracheostomy or intubation. 8, 15, 18, 19, 21 Th e diagnosis is defi nitive when spherules are seen in sputum or tissue or when Coccidioides is grown by culture. 4, 10, 16, 17 Culture produces the mycelial form, which is extremely infectious because arthroconidia are easily displaced and made airborne. Laboratory personnel are at risk of infection, so precautions must be in place for workers who handle these cultures. 16 Th e disease stage in humans is not considered infectious because the spherule/endospore stage does not aerosolize. Unless direct inoculation has occurred-for example, as a result of contact with infected dressings or in the rare case of exposure to cavitary lung lesions and sputum-person-to-person transmission does not occur. 17 Skin testing with coccidioiden will demonstrate positivity if a patient has had such an infection at any time in the past. A test result can convert from negative to positive at any time from 3 days to 3 weeks aft er infection. Unless a conversion reaction is seen, it is not possible to distinguish a "current" infection from a positive skin test. In fact, many people who live in endemic areas will have a positive skin test with no identifi able illness. 17 Skin tests may become negative when progressive disseminated disease occurs and anergy develops. 4, 17 Serologic tests can be helpful; serum IgM is detectable temporarily in three-fourths of patients with primary infection. 4 Th is immunoglobulin will disappear within a few months and be replaced by IgG. Th e serum IgG level is also known as the complement-fi xation antibody titer, and it can be quantifi ed. Rising titers can be an indicator of disseminated disease, although there is debate as to which titer indicates such dissemination, particularly because some patients with coccidioidal meningitis have low or absent titers. 4, 8, 11, 17, 19, 22, 26 Changes in titers may be used to monitor treatment success. 4, 16 In the past 3 years, additional diagnostic tests have been evaluated. Th ese include immunodiff usion tube precipitin and complement-fi xation assays, enzymelinked immunosorbent assay (ELISA) for IgM or IgG, Coccidioides antigenemia, in situ hybridization of locked nucleic acids, genomic analysis of ribosomal RNA, and real-time polymerase chain reaction. [27] [28] [29] Concerns exist, however, in using these diagnostic tests because of cross-reactivity with other fungal species and high rates of false-positive tests, particularly with ELISA and antigenemia assays. 27, 30, 31 Genomic analysis test kits have yet to become commercially available. 27 Treatment with systemic antifungal medication, pri-marily amphotericin B combined with an azole agent, has proven to be eff ective in controlling symptoms and eradicating disease in most cases. 4, 5, 8, 15, 21, 32 It is not known how long treatment should be continued, but a longer course (i.e., ≥1 yr) has been preferred in most centers. 4, 15 Reactivation of disease warrants extended treatment. 5 Debridement or resection of grossly involved tissue has been performed in some circumstances, such as bony infection or in the presence of cavitated lung lesions. 4, 11 Kafk a and Catanzaro advocated surgical debridement combined with antifungal therapy for any disseminated infection that involves bony, cutaneous, and subcutaneous sites. 11 In conclusion, coccidioidal infection of the airway is an unusual but important cause of airway distress. Th e diagnosis requires a high index of suspicion, especially in endemic areas, and appropriate tissue for culture and biopsy. Coccidioidomycosis may be associated with protean symptoms and signs that may not be temporally related. Treatment requires systemic antifungal medication and sometimes surgical intervention. Patients should be followed long term and promptly reassessed if new or recurrent symptoms develop. Although it is rare, coccidioidomycosis should be considered in the diff erential diagnosis of patients in endemic areas presenting with laryngeal symptoms.
